20/20 Biolabs Common Stock Overview
Valuation check: AIDX's ROE is -428.7%, below the sector sector average of -5.72%.
Get informed when a big investor buys or sells
+ Follow-428.70%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
20/20 Biolabs Common Stock's return on equity stands at -428.7%. That is below the sector sector average of -5.72%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
20/20 Biolabs Common Stock sits lower the its sector benchmark (-5.72%) with a ROE of -428.7%. That is roughly 7391.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -428.7% for 20/20 Biolabs Common Stock means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how 20/20 Biolabs Common Stock's ROE evolved across reporting periods, while the comparison chart places AIDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
